Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, treating androgenic alopecia with catgut embedment, moxibustion, and bloodletting showed better results after 3 months than finasteride, potentially due to decreased testosterone levels and testosterone/estradiol ratios.

Cyproterone acetate therapy improved hair loss and reduced testosterone levels in a menopausal woman.

This study found that lifestyle interventions improved body composition, hyperandrogenism, and insulin resistance in women with PCOS, but did not affect glucose tolerance, lipid profiles, or clinical reproductive outcomes.

In this study, cross-sex hormone therapy affected hair growth patterns differently, with estrogen reducing hair growth in male-to-female transsexuals and testosterone increasing it in female-to-male transsexuals; however, male typical hair diameters were not fully reached in the latter group after 12 months.

In this study, spearmint tea significantly reduced testosterone levels and improved self-reported hirsutism in women with PCOS, but did not change objective hair growth scores over the short trial period.

This study found that nafarelin treatment significantly reduced androgen levels and improved hirsutism symptoms in women, suggesting it may be useful for managing this condition.

In this study, finasteride doses as low as 0.2 mg per day significantly reduced both scalp skin and serum DHT levels in men with androgenetic alopecia.

This study found that myo-inositol treatment reduced hirsutism and acne in women with PCOS by improving their metabolic profiles, including lower insulin and testosterone levels.

In this study, treatment with the oral contraceptive containing 30 μg ethinyl oestradiol and 150 μg desogestrel significantly reduced androgen-dependent hair growth in hirsute women over one year.

This study found that cyproterone acetate, given with ethinyl oestradiol, significantly reduced hirsutism in women after 12 months, although improvements reversed once cyproterone acetate was stopped.

In this study on rats, rutin showed dose-dependent improvements in hormonal, antioxidant, and lipid profiles related to polycystic ovary syndrome, with effects comparable to metformin.

This review discusses the clinical and molecular history of 5-alpha reductase deficiency, highlighting its role in male sexual differentiation and potential therapeutic applications, but reports no new research outcomes.

This study found that antisense oligonucleotides can significantly reduce androgen receptor expression in cultured human sebocytes and may offer new therapeutic possibilities for androgen-associated skin diseases.

This study found that androgenic steroids, particularly androstenedione and androstanedione, significantly reduced the growth of certain dermatophytes, suggesting hormonal influence on fungal infections in hair follicles.

This study found that administering spironolactone or canrenone to castrated male rats significantly decreased the availability of cytoplasmic androgen receptor binding sites, suggesting canrenone mediates spironolactone's antiandrogenic effects in skin.

This study reports that oophorectomy significantly reduces serum testosterone levels in postmenopausal women, indicating the postmenopausal ovary's continued production of testosterone.

This study found that combined Myo-inositol and D-chiro-inositol therapy improved metabolic and hormonal parameters, including weight, hormone levels, and skin conditions, in women with PCOS after 6 months.

This study found that an 8-week low-starch/low-dairy diet led to weight loss, improved insulin sensitivity, and reduced testosterone levels in women with PCOS.

This study found that high-dose cyproterone acetate was effective for treating hirsutism, but 33% of patients felt their condition worsened on low-dose maintenance therapy, despite no significant change in objective measures of hair growth.

This review summarizes recent advancements in steroidal 5α-reductase inhibitors for benign prostatic hyperplasia and reports no new clinical results.

This review discusses the effects of 5ARI drugs on male reproductive parameters, reporting potential decreases in sperm count and motility more significantly in men with pre-existing oligozoospermia, but does not provide fertility outcomes.

Nandrolone and oxandrolone could help treat male health issues like muscle loss and low testosterone.

This study found that male 5α-reductase 2 knockout mice showed deficits in social dominance behaviors and reduced dopamine receptor binding in a brain region related to social ranking.

This study found that both cyproterone acetate alone and combined with ethinyl oestradiol reduced androgen levels and slightly increased SHBG binding in women with hirsutism, but showed no difference in hair regrowth rate between the treatments.

In this study, 12 months of cyproterone acetate and ethinyl oestradiol treatment significantly reduced hair growth rate and certain hormone levels in hirsute women, though hair density and prolactin levels remained unchanged.

This study found that combining low-dose spironolactone with metformin improved insulin resistance in PCOS patients more effectively than using either drug alone.

This source suggests that migraine prevalence increases in transgender women using oestrogen and decreases in transgender men using testosterone, with high oral oestrogen doses in transgender women potentially linked to aura risk.

This study found that proxalutamide improved immunologic, inflammatory, thrombotic, and oxygen markers in both female and male COVID-19 outpatients, which may support its association with lower hospitalization rates compared to standard care.

This study found that parenteral administration of cyproterone acetate was more effective than high-dose oral treatment in reducing facial hair diameter and improving dermatological parameters in patients with severe hirsutism, despite similar androgen suppression.

This study found that orlistat significantly reduced weight and total testosterone levels in Iranian women with polycystic ovary syndrome after 12 weeks of treatment.